Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting
24 Abril 2024 - 9:00AM
Business Wire
- Oral presentation of preliminary results from Phase 1 study of
OBX-115, a novel engineered tumor-derived autologous T cell
immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy)
armored with pharmacologically regulatable membrane-bound IL15
(mbIL15), in patients with advanced or metastatic melanoma
- Additional trial-in-progress poster presentation outlining the
details of the ongoing Phase 1/2 trial of OBX-115 in patients with
advanced solid tumors
Obsidian Therapeutics, Inc., a clinical-stage biotechnology
company pioneering engineered cell and gene therapies, today
announced two presentations, including an oral presentation on the
Phase 1 first-in-human study of OBX-115, a novel engineered
tumor-derived autologous T cell immunotherapy (tumor-infiltrating
lymphocyte [TIL] cell therapy) armored with pharmacologically
regulatable membrane-bound IL15 (mbIL15), in patients with immune
checkpoint inhibitor (ICI)-resistant advanced or metastatic
melanoma (NCT05470283), at the 2024 American Society of Clinical
Oncology (ASCO) Annual Meeting, taking place in Chicago on May
31–June 4.
Oral Poster Presentation
- Title: OBX-115, an interleukin 2 (IL2)-sparing
engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in
patients (pts) with immune checkpoint inhibitor (ICI)-resistant
unresectable or metastatic melanoma.
- Session Title: Rapid Oral Abstract – Melanoma/Skin
Cancers
- Date and Time: Monday, June 3, at 9:45 a.m. CT/10:45
a.m. ET
- Abstract Number: 9515
- Speaker/Lead Author: Rodabe N Amaria, M.D., The
University of Texas MD Anderson Cancer Center
- Clinical Trial Identifier: NCT05470283 (First-in-human
study)
Trials in Progress Poster Presentation
- Title: A phase 1/2 study to investigate the safety and
efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL)
cell therapy in patients (pts) with advanced solid tumors.
- Session Title: Poster Session – Melanoma/Skin
Cancers
- Date and Time: Saturday, June 1, at 1:30 p.m. CT/2:30
p.m. ET
- Abstract Number: TPS9599
- Speaker/Lead Author: Adam J Schoenfeld, M.D., Memorial
Sloan Kettering Cancer Center
- Clinical Trial Identifier: NCT06060613 (Multicenter
study)
About OBX-115
Obsidian’s lead investigational cytoTIL15™ program, OBX-115, is
a novel engineered tumor-derived autologous T cell immunotherapy
(tumor-infiltrating lymphocyte [TIL] cell therapy) armored with
pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115
has the potential to become a meaningful therapeutic option for
patients with advanced or metastatic melanoma and other solid
tumors by leveraging the expected benefits of mbIL15 and Obsidian’s
proprietary, differentiated manufacturing process to enhance
persistence, antitumor activity, and clinical safety of TIL cell
therapy. OBX-115 is being investigated in two ongoing and enrolling
clinical trials in advanced or metastatic melanoma and NSCLC
(NCT05470283 and NCT06060613).
About Obsidian Therapeutics
Obsidian Therapeutics, Inc. is a clinical-stage biotechnology
company pioneering engineered cell and gene therapies to deliver
transformative outcomes for patients with intractable diseases.
Obsidian’s proprietary cytoDRiVE® technology is designed to
precisely regulate the timing and level of protein function by
using FDA-approved small-molecule drugs. Obsidian is headquartered
in Cambridge, MA. The Company has collaborations with Bristol Myers
Squibb and Vertex Pharmaceuticals. For more information, please
visit www.obsidiantx.com and follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240424758976/en/
Media: david.rosen@argotpartners.com 212-600-1902